By MLex Staff ( January 7, 2021, 08:14 GMT | Insight) -- Yangtze River Pharmaceutical, one of China's largest pharmaceutical makers, is accused of controlling resale prices of multiple drugs in an ongoing investigation by the country's competition regulator, MLex has learned. The Chinese pharma giant allegedly imposed resale price maintenance, or RPM, restrictions in some commonly used drugs, prompting a state-level probe that has been going on for more than a year, it is understood.Yangtze River Pharmaceutical, one of China's largest pharmaceutical makers, is accused of controlling resale prices of multiple drugs in an ongoing investigation by the country's competition regulator, MLex has learned....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.